What is HC Wainwright’s Forecast for NRIX FY2026 Earnings?

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Stock analysts at HC Wainwright lowered their FY2026 earnings per share (EPS) estimates for Nurix Therapeutics in a research note issued to investors on Friday, October 16th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($2.99) for the year, down from their previous estimate of ($2.91). HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is $1.15 per share. HC Wainwright also issued estimates for Nurix Therapeutics’ Q4 2026 earnings at ($0.33) EPS, Q1 2027 earnings at ($0.57) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.61) EPS and Q4 2027 earnings at ($0.64) EPS.

Several other equities analysts have also recently issued reports on NRIX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a research note on Thursday. Oppenheimer raised their target price on shares of Nurix Therapeutics from $28.00 to $32.00 and gave the company an “outperform” rating in a report on Tuesday, October 13th. BTIG Research reiterated a “buy” rating and issued a $32.00 price target on shares of Nurix Therapeutics in a research note on Friday, July 10th. Truist Financial dropped their target price on Nurix Therapeutics from $34.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, October 13th. Finally, Royal Bank Of Canada lowered their price objective on Nurix Therapeutics from $36.00 to $35.00 and set an “outperform” rating for the company in a research report on Tuesday, October 13th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Nurix Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $34.79.

Nurix Therapeutics Price Performance

Shares of NASDAQ NRIX opened at $24.93 on Tuesday. The company has a market cap of $2.72 billion, a price-to-earnings ratio of 10.79 and a beta of 1.82. The stock’s 50-day moving average is $25.09 and its two-hundred day moving average is $21.27. Nurix Therapeutics has a 1-year low of $9.93 and a 1-year high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Monday, October 12th. The company reported $4.73 EPS for the quarter, topping the consensus estimate of ($0.60) by $5.33. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. The firm had revenue of $673.06 million during the quarter, compared to analysts’ expectations of $24.35 million.

Insider Transactions at Nurix Therapeutics

In related news, Director Julia P. Gregory sold 22,583 shares of the company’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $23.40, for a total value of $528,442.20. Following the completion of the sale, the director directly owned 10,750 shares of the company’s stock, valued at $251,550. This represents a 67.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Hans van Houte sold 4,761 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total value of $115,977.96. Following the transaction, the chief financial officer owned 40,166 shares in the company, valued at $978,443.76. This represents a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 45,407 shares of company stock worth $1,083,206. Corporate insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in NRIX. GAMMA Investing LLC increased its stake in Nurix Therapeutics by 95.4% in the third quarter. GAMMA Investing LLC now owns 1,270 shares of the company’s stock valued at $30,000 after purchasing an additional 620 shares during the period. Nykredit A S purchased a new stake in shares of Nurix Therapeutics in the second quarter valued at about $32,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Nurix Therapeutics during the second quarter worth about $33,000. KBC Group NV acquired a new stake in shares of Nurix Therapeutics during the first quarter worth about $34,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Nurix Therapeutics during the fourth quarter worth about $53,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.